ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy
about
p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the StoryRedundancy in the World of MAP Kinases: All for OneMicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemiaCM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemiaForced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatmentSnail promotes epithelial mesenchymal transition in breast cancer cells in part via activation of nuclear ERK2.A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.Using functional genomics to overcome therapeutic resistance in hematological malignancies.MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.MAPK15 mediates BCR-ABL1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation.Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5)·extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1.Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.Current status of agents active against the T315I chronic myeloid leukemia phenotype.Grb10 is involved in BCR-ABL-positive leukemia in mice.Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib.
P2860
Q26742078-F9BCE00B-D0DB-4FCB-B142-F33170CF8E80Q26742080-34C1F9A4-689C-49EE-B0D9-38E4AEED48E5Q26766288-5AE86178-D5CD-42EB-84FE-F51156B7CB20Q33728096-4AB6DCD4-0C06-47DA-A77E-52A9136BACE4Q33887799-385D78EE-B4DB-437D-9C3E-CA37A9C53E0EQ34047362-D240EC1E-5A05-4151-8DAE-3B23C7C6E507Q34170309-AC8BDF87-CAEC-463F-972E-5278CF37D011Q34401328-5102B8F0-CD10-459F-9DBB-6A1BA5067D69Q35905629-00DE0394-E07D-492C-8464-6BDBD099A6D9Q36777169-749BE20A-698D-43F5-94A9-2B4965564250Q37583522-0AA7489F-4BEC-458A-BC78-903BBD279C64Q37836931-8105F430-9C44-4A5B-BFF5-64BC04537FAFQ37847179-8C7F758D-E148-475A-A249-18B7713D0A9DQ38953915-49D3D24E-63E7-4F0B-A7A0-72DE548ABEE1Q40971143-A3A8457A-83D4-41DA-A854-D3213F6F92D5Q47134648-2D65717B-78E8-46B7-AE56-4325C706F55BQ52715766-384BF884-83BE-46CF-9D4A-51B4A90E09CF
P2860
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
ERK2, but not ERK1, mediates a ...... e: implication for CML therapy
@ast
ERK2, but not ERK1, mediates a ...... e: implication for CML therapy
@en
type
label
ERK2, but not ERK1, mediates a ...... e: implication for CML therapy
@ast
ERK2, but not ERK1, mediates a ...... e: implication for CML therapy
@en
prefLabel
ERK2, but not ERK1, mediates a ...... e: implication for CML therapy
@ast
ERK2, but not ERK1, mediates a ...... e: implication for CML therapy
@en
P2093
P2860
P1433
P1476
ERK2, but not ERK1, mediates a ...... e: implication for CML therapy
@en
P2093
Anupriya Agarwal
Atanasio Pandiella
Clara I Aceves-Luquero
Eva M Galán Moya
Inmaculada Moreno Gimeno
Itxaso Bellón-Echeverria
Juan C Gómez
Juan L Callejas-Valera
Laura Arias-González
Luis del Peso Ovalle
P2860
P356
10.1371/JOURNAL.PONE.0006124
P407
P577
2009-07-01T00:00:00Z